Peginterferon alfa-2a (40KD): A potent long-acting form of interferon alfa-2a for the treatment of hepatitis C

Advances in Experimental Medicine and Biology

Volumn 519, Issue , 2003, Pages 59-67

  Modi, Marlene W ^a   Lamb, Matthew W ^a   Shiomi, Mari ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A;

CONFERENCE PAPER; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; TREATMENT PLANNING;

ANTIVIRAL AGENTS; CLINICAL TRIALS; EXCIPIENTS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS;

HEPATITIS C VIRUS;

EID: 0038633509     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (26)

1. Sharara, A.I., Hunt, C.M., et al., 1996, Hepatitis C. Ann Intern Med 125:658-68.
2. Koziel, M.J., 1996, Immunology of viral hepatitis. Am J Med 100:98-109.
3. Kiyasu, P.K. and Caldwell, S.H., 1993, Diagnosis and treatment of the major hepatotropic viruses. Am J Med Sci 306: 248-61.
4. Iwarson, S., Norkraus, G. et al., 1995, Hepatitis C: natural history of a unique infection. Clin Infect Dis 20: 1361-70.
5. Alter, M., 1997, Epidemiology of hepatitis C. Hepatology 26:(3 Suppl 1): 625-655.
6. Davis, G.L., 2000, Current therapy for chronic hepatitis C. Gastroenterol 118 (Suppl 1): S104-S114.
7. Lawrence, S.P., 2000, Advances in the treatment of hepatitis C. In Advances in Internal Medicine. Mosby, St. Louis.
8. Hoofnagle, J.H. and di Bisceglie, A.M., 1997, The treatment of chronic viral hepatitis. N Engl J Med 336: 347-56.
9. McHutchinson, J.G., Gordon, S.C., et. al., 1998, Interferon alfa-2b or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 1485-92.
10. Wills, R.J., 1990, Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19: 390-399.
11. Bocci, V., Pacini, A. et. al., 1981, Renal filtration, absorption and catabolism of human alpha interferon. J Interferon Res 1: 347-52.
12. Zeuzem, S., Herrmann, E. et. al., 2001, Viral kinetics with chronic hepatitis C patients treated with standard or peginterferon alfa-2a. Gastroenterol 120: 1438-1447.
13. Laim, N.P. Neumann, A.U. et. al., 1997, Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26: 226-31.
14. Zhi, J., Teller, S.B. et al., 1995, Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2b given by subcutaneous injection in healthy male volunteers. J Clin Pharmacol 35: 281-4.
15. Harris, J.M., Martin, N.E., et. al., 2001, Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40: 539-51.
16. Yamaoka, T., Tabata, Y., et. al., 1994, Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 83: 601-6.
17. Fung, W.-J., Porter, J.E., et. al., 1997, Strategies for the preparation and characterization of polyethylene glycol vinyl sulfone. Polymers Preprint: 565-66.
18. Nieforth, K.A., Nadeau, R., et. al., 1996, Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 59: 636-46.
19. Xu, Z.-X., Patel, I., et al., 1998, Single-dose safety, tolerability and pharmacokinetics of PEG-FIN alfa-2a and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 28 (Suppl): 702.
20. Bailon, P., Palleroni, A., et al., 2001, Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chem 12: 195-202.
21. Bailon, P., Spence, C., et al., 1999, Pharmacokinetic properties of five polyethylene glycol conjugates of interferon alfa-2a. Antiviral Therapy 4 (Suppl 4): 27.
22. Harris, N.J., Veronese, F.M., et al., 1999, Multiarmed, monofunctional, polymer for coupling to molecules and surfaces. US Patent & Trademark Office, USA.
23. Algranati, N.E., Sy, S., et. al., 1999, A branched methoxy 40 kDa, polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of PEG-IFN alfa-2a and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 40: 190.
24. Modi, M.W., Fried, M.W., et. al., 2000, The pharmacokinetic behavior of pegylated (40 kDa) interferon alfa-2a (PEGASYS) in chronic hepatitis patients after multiple dosing. Hepatology 32 (4 Pt 2 of 2): 394A.
25. Zeuzem, S., Feinman, S.V., et al., 2000, Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343: 1666-72.
26. Heathcote, E.J., Shiffman, M.J., et. al., 2000, Pegintefferon alfa-2a in patieints with chronic hepatitis C and cirrhosis. N Engl J Med 345: 1673-80.